Small Business: Small Molecule Therapeutic Development for Alzheimer’s Disease, Related Dementias and Neurodegenerative Disorders – NPB (10)
This review panel reviews applications dealing with basic and clinical aspects of drug discovery in treatment of aging and neurodegenerative disorders, including mild-cognitive impairment, Alzheimer’s disease and related dementias, movement degenerative disorders such as Parkinson’s, Huntington’s, amyotrophic lateral sclerosis. Approaches are those of medicinal chemistry and pre-clinical development, toxicology, and some clinical studies to establish proof-of-principle for new or repurposing existing drugs. The therapeutic formats studied in NPB 10 focus on small molecule drugs.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Interventions for senescence of nerve cells, cognitive aging, and mild cognitive impairment (MCI)
- Alzheimer’s disease (AD)
- Alzheimer’s related dementia (ADRD) including frontotemporal dementia (FTD), Lewy body dementia (LBD), Limbic-predominant age-related TDP-43 encephalopathy (LATE), and Creutzfeldt-Jakob disease (CJD)
- Neurodegenerative movement disorders such as Parkinson’s diseases (PD), essential tremor, ataxia, Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), etc.
- Approaches utilized include small molecule development, medicinal chemistry, pK/pD and toxicology studies.
The range of studies include target identification, target validation, and target optimization in in vitro/ex vivo, pre-clinical as well as proof of principle early stage clinical studies.
